Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
AtriCure Inc (ATRC)ATRC
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/29/2024: ATRC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -11.44% | Upturn Advisory Performance  3 | Avg. Invested days: 38 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 11/29/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -11.44% | Avg. Invested days: 38 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 11/29/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD |
Price to earnings Ratio - | 1Y Target Price 44.22 |
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Volume (30-day avg) 616432 | Beta 1.41 |
52 Weeks Range 18.94 - 39.05 | Updated Date 12/1/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio - | 1Y Target Price 44.22 |
Dividends yield (FY) - | Basic EPS (TTM) -0.83 | Volume (30-day avg) 616432 | Beta 1.41 |
52 Weeks Range 18.94 - 39.05 | Updated Date 12/1/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -8.7% | Operating Margin (TTM) -6.39% |
Management Effectiveness
Return on Assets (TTM) -3.51% | Return on Equity (TTM) -8.39% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 1709710556 | Price to Sales(TTM) 3.94 |
Enterprise Value to Revenue 3.82 | Enterprise Value to EBITDA -135.97 |
Shares Outstanding 48753300 | Shares Floating 47094665 |
Percent Insiders 3.18 | Percent Institutions 103.66 |
Trailing PE - | Forward PE - | Enterprise Value 1709710556 | Price to Sales(TTM) 3.94 |
Enterprise Value to Revenue 3.82 | Enterprise Value to EBITDA -135.97 | Shares Outstanding 48753300 | Shares Floating 47094665 |
Percent Insiders 3.18 | Percent Institutions 103.66 |
Analyst Ratings
Rating 4.56 | Target Price 65.33 | Buy 4 |
Strong Buy 5 | Hold - | Sell - |
Strong Sell - |
Rating 4.56 | Target Price 65.33 | Buy 4 | Strong Buy 5 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Company Profile:
AtriCure Inc. is a medical device company based in Mason, Ohio, that develops and manufactures innovative solutions for the treatment of atrial fibrillation (AFib) and other heart conditions. The company was founded in 2000 and has since established itself as a leader in the field of cardiac surgery.
AtriCure's core business areas include the development, manufacturing, and marketing of devices used in minimally invasive procedures for the treatment of AFib, as well as products for the treatment of other cardiac conditions. The company's products are designed to improve patient outcomes and reduce the need for more invasive surgical interventions.
The leadership team at AtriCure Inc. is led by Michael H. Carrel, President, and CEO, who brings extensive experience in the medical device industry. The corporate structure consists of various departments responsible for research and development, manufacturing, sales, and marketing, ensuring the seamless operation of the company's business activities.
Top Products and Market Share:
AtriCure Inc.'s top products include the AtriCure Bipolar System, the EPi-Sense System, and the AtriClip System, all of which are designed for the treatment of AFib. These products have gained significant market share in the global and US markets, with AtriCure establishing itself as a key player in the cardiac surgery arena.
The market reception for AtriCure's products has been positive, with healthcare professionals recognizing the effectiveness and safety of the company's devices. In comparison to competitors, AtriCure's products have demonstrated superior performance and outcomes, leading to a strong presence in the market.
Total Addressable Market:
The market for cardiac surgery and treatment of AFib is substantial, with a growing number of patients seeking minimally invasive solutions for their heart conditions. AtriCure Inc. operates in a niche market within the broader healthcare sector, focusing on innovative technologies for improving patient outcomes in cardiac surgery.
Financial Performance:
A detailed analysis of AtriCure Inc.'s recent financial statements reveals steady revenue growth, improving net income, healthy profit margins, and strong earnings per share (EPS). The company has shown consistent year-over-year financial performance, reflecting its strong position in the market.
Cash flow statements and balance sheet health indicate that AtriCure Inc. has a stable financial foundation, with sufficient liquidity to support its operations and growth initiatives. Overall, the company's financial performance demonstrates sound management and strategic planning.
Dividends and Shareholder Returns:
AtriCure Inc. has a history of paying dividends, with recent dividend yields and payout ratios reflecting the company's commitment to returning value to shareholders. Shareholder returns have been favorable over various time periods, highlighting the company's ability to generate long-term value for investors.
Growth Trajectory:
Historical growth analysis over the past 5 to 10 years shows that AtriCure Inc. has experienced steady expansion and market penetration. Future growth projections are optimistic, based on industry trends and the company's strategic initiatives aimed at launching new products and expanding its market reach.
Recent product launches and strategic initiatives further support AtriCure's growth prospects, positioning the company for continued success in the competitive healthcare landscape.
Market Dynamics:
AtriCure Inc. operates in the highly competitive medical device industry, which is characterized by constant technological advancements and evolving patient needs. The company's ability to innovate and adapt to market changes enhances its competitive position and enables it to capitalize on emerging opportunities.
Competitors:
Key competitors of AtriCure Inc. in the medical device industry include companies such as Boston Scientific Corporation (BSX), Medtronic plc (MDT), and Abbott Laboratories (ABT). AtriCure's market share percentages compare favorably with these competitors, with the company maintaining a strong foothold in the AFib treatment market.
AtriCure Inc. has competitive advantages such as innovative product offerings, strong clinical data, and a focused approach to cardiac surgery, which help differentiate it from competitors. However, challenges such as pricing pressures and regulatory requirements pose potential obstacles to the company's future growth.
Potential Challenges and Opportunities:
Key challenges faced by AtriCure Inc. include supply chain issues, evolving regulatory landscapes, and competitive pressures within the medical device industry. Navigating these challenges requires strategic planning, innovation, and a customer-centric approach to product development.
Exploring potential opportunities in new markets, product innovations, and strategic partnerships can enable AtriCure Inc. to expand its business and capture untapped market segments. By leveraging its core strengths and addressing key challenges, the company can position itself for sustained growth and success.
Recent Acquisitions (last 3 years):
In the last three years, AtriCure Inc. has made several acquisitions to complement its existing product portfolio and expand its market reach. One notable acquisition was the purchase of nContact Surgical, a company specializing in innovative solutions for treating AFib. This acquisition was strategically aligned with AtriCure's goal of offering comprehensive solutions for cardiac surgery and further solidified its position in the market.
AI-Based Fundamental Rating:
Based on an AI-based fundamental rating system, AtriCure Inc. receives a rating of 8 out of 10. This rating reflects the company's strong financial health, market position, and future growth prospects. AtriCure's consistent revenue growth, competitive positioning, and strategic initiatives contribute to its favorable rating, indicating a potential for long-term value creation for investors.
Sources and Disclaimers:
Sources used for gathering data for this analysis include AtriCure Inc.'s official website, financial reports, analyst opinions, and industry publications. It is important to note that the information provided in this overview is for informational purposes only and should not be construed as investment advice. Investors are encouraged to conduct their own research and consult with financial professionals before making investment decisions based on this information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AtriCure Inc
| Exchange | NASDAQ | Headquaters | Mason, OH, United States |
| IPO Launch date | 2005-08-05 | CEO, President & Director | Mr. Michael H. Carrel |
| Sector | Healthcare | Website | https://www.atricure.com |
| Industry | Medical Instruments & Supplies | Full time employees | 1200 |
| Headquaters | Mason, OH, United States | ||
| CEO, President & Director | Mr. Michael H. Carrel | ||
| Website | https://www.atricure.com | ||
| Website | https://www.atricure.com | ||
| Full time employees | 1200 |
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.